Introduction: A plethora of options are available in the management of renal masses suspected to be malignant. We aimed to compare oncological outcomes, morbidity, renal function and peri-operative outcomes between Cryotherapy (CA) and Robotic Assisted Partial Nephrectomy (RAPN) for renal masses.
Are emergency admissions with visible haematuria waiting longer for diagnostics than those referred on the suspected urological cancer pathway?
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Background There is evidence that prompt treatment of solid bladder cancer influences outcome. NICE guidelines recommend that patients seen in primary care with a suspected urological cancer should be referred to a specialist and undergo investigation within a 2-week time frame. However, the diagnostic pathway may differ for patients requiring urgent admission for gross visible haematuria (GVH).
Aim
Primary outcome measure -time to flexible cystoscopy Secondary outcome measures -time to TURBT and histological stage
Method
We performed a retrospective case note review of patients undergoing investigations for haematuria over 12 months. Inclusion criteria were those presenting as an emergency admission with GVH and those referred from primary care with VH on a suspected urological cancer pathway. Exclusion criteria were previous diagnosis of bladder cancer or other known cause of GVH. Data collected included patient demographics, time from referral to flexible cystoscopy/TURBT and histopathological data.
Results
We identified 431 patients in total. 389 were referred on a suspected urological cancer pathway with a mean age of 66.7(range 27-92)yrs and mean time to flexible cystoscopy of 13.6(range 3-62)days, and 42 presented as an emergency admission with VH with a mean age of 75.4(range 34-95)yrs and a mean time to flexible cystoscopy of 33.5(range 5-68)days p=<0.0001. Mean time to TURBT was also found to be longer in the emergency group, 51.2(range 23-66) days compared to 39.2(range 14-73)days for patients on the pathway demonstrating a trend towards delay. All of the bladder tumours identified in the patients presenting as an emergency were high-grade urothelial tumours.
Conclusion
Patients presenting as an emergency with GVH are waiting longer for diagnostics than those referred on a suspected urological cancer pathway. This results in a delay to definitive diagnosis and treatment in a group of patients with potentially high-grade, high-risk tumours.
Introduction
There is evidence supporting the role of radiotherapy (RT) after radical prostatectomy (RP) in the management of high-risk prostate cancer. However, concerns remain about the associated treatmentrelated toxicity, patient inconvenience and costs.
Aim
To evaluate the impact of modality and timing of post-prostatectomy RT on severe genitourinary (GU) and gastrointestinal (GI) toxicity.
Methods
National population-based study of all patients treated with post-prostatectomy radiotherapy (RT) between January 1 2010 and December 31 2013 in England. A validated coding system captured severe toxicity (≥ Grade 3 according to the NCI CTCAE criteria) following RT. A competing-risks regression analysis was used to estimate hazard ratios (HR) comparing severe late toxicity between the following groups: (i) 3D-conformal radiotherapy (3D-CRT) vs Intensity-modulated radiotherapy (IMRT), (ii) RT within 6 months of RP vs RT more than 6 months after RP.
Results
There was no difference in severe GI toxicity between patients who received IMRT and 3D-CRT (3D-CRT: 5.8 events/100 person years; IMRT: 5.5 events/100 person years; adjusted HR: 0.85, 95% CI: 0.63-1.13; p=0.26). The rate of severe GU toxicity was lower with IMRT but this was not statistically significant (3D-CRT: 5.4 events/100 person years; IMRT: 3.8 events/100 person years; adjusted HR: 0.76, 95% CI: 0.55-1.03; p=0.08). Men who started RT more than 6 months after RP were less likely to experience GU toxicity than those who started RT within 6 months (adjusted HR: 0.72, 95% CI: 0.59-0.89; p<0.01).
Conclusion
The use of IMRT compared to 3D-CRT is not associated with a statistically significant reduction in rates of severe GU and GI toxicity in the post-prostatectomy setting. Starting RT at least 6 months after surgery reduced GU toxicity. Given these findings, we would caution the transition to IMRT in the postprostatectomy setting and recommend waiting at least 6 months before the start of RT following RP.
